Wadi Al-Rafidain Company

What Wadi Al-Rafidain Company does

Wadi Al-Rafidain Company (legal name: Al Rafidain Pharmaceutical Production Company) is a private-sector Iraqi pharmaceutical manufacturer established in 1998 in Baghdad. The company produces generic human medicines across four production departments — tablets, powders, syrups and suspensions, and ointments and creams — with a catalog of over 126 SKUs spanning analgesics, antibiotics, antihistamines, anti-inflammatories, antacids, vitamins, and supplements. Manufacturing is conducted under WHO Good Manufacturing Practice (GMP) standards, monitored through internal quality control laboratories, and the company employs over 100 staff across scientific and commercial disciplines who receive ongoing training through partnerships with international institutes.

The business operates a hybrid B2B/B2C distribution model. A medical promotion team composed of doctors and pharmacists pushes product into healthcare providers and pharmacies, while sales depots distributed across all Iraqi provinces handle physical distribution. Three main depots in Baghdad coordinate provincial commercial and pharmaceutical promotion activities. Go-to-market is therefore enterprise field sales through wholesale/distributor-style depots, supplemented by direct medical detailing. Pricing is not publicly disclosed and revenue model information is unavailable; the company has no online ordering platform, mobile app, or disclosed digital sales channel.

The company monetizes solely through one-time sale of physical pharmaceutical products, with no subscription, licensing, or platform revenue streams. End customers are fragmented — pharmacies and healthcare providers across Iraq — with no single named anchor account disclosed. Operational scale signals (100+ staff, 126+ SKUs, nationwide depots) suggest a mid-sized regional manufacturer rather than a multinational or startup, and the firm has not disclosed patents, trademarks, awards, partnerships, or external funding rounds in the available data.

Name

Wadi Al-Rafidain Company

Legal name

Al Rafidain Pharmaceutical Production Company

Website

https://alrafidain-pharma.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Wadi Al-Rafidain Company is a Baghdad-based, WHO GMP-compliant pharmaceutical manufacturer founded in 1998, producing generic human medicines — tablets, syrups, ointments, and creams — and distributing them through provincial sales depots to pharmacies and healthcare providers across all of Iraq.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Specialty Pharmaceutical Distributors (HLAIAJAB)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Human medicines
• Tablets and syrups
• Topical ointments

Headquarters

HQ city

Bagdad

HQ country

Iraq

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: The company generates revenue through the production and sale of human medicines including tablets, syrups, suspensions, powders, ointments, and creams to consumers across Iraq.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Wadi Al-Rafidain Company manufactures and distributes generic human medicines in four dosage formats — tablets, powders, syrups and suspensions, and ointments and creams — from its WHO GMP-compliant facility in Baghdad. The portfolio spans analgesics, antibiotics, anti-inflammatories, antihistamines, antacids, vitamins and supplements, and reaches Iraqi consumers through sales depots and medical promotion teams in all Iraqi provinces.

Product overview

Wadi Al-Rafidain Company (Al Rafidain Pharmaceutical Production Company) is a pharmaceutical manufacturer producing a diverse portfolio of generic medicines organized into four primary product categories: Syrups and Suspensions (including Syrup, Oral Suspension, Oral Drop, Elixir, Oral Solution for Children, and flavored suspensions like GASTEREDAIN PLUS Banana Flavor and GASTEREDALIN PLUS Mint Flavor), Powders, Tablets (including Chewable Tablets, Coated Tablets, Sugar Coated Tablets, and Caplets such as Panadain Advance/Day/Extra/Night, MEFENADAIN, PREZOLDAIN, Ciprodain, NAPROXDAIN, and antibiotics like LIBROXADAIN), and Ointments and Creams (including Creams, Ointments, Rectal Ointment, and Gel). The company operates as a single-product pharmaceutical manufacturing business with no platform architecture, offering products across therapeutic areas including analgesics, anti-inflammatories, antihistamines, antibiotics, antacids, vitamins, and supplements. The product line spans from common over-the-counter remedies like Panadain and vitamin supplements to prescription antibiotics and anti-inflammatory medications.

Differentiator

Problem solved

Functional benefit

Products and services

• MEFENADAIN Tablets Non-steroidal anti-inflammatory drug (NSAID) tablets available in 250 mg and 500 mg strengths for pain and inflammation relief; for healthcare providers, pharmacies and end consumers in Iraq.
• Panadain Advance tablet Analgesic and antipyretic tablet for pain and fever relief.
• Panadain Day tablet Daytime analgesic tablet for pain and fever relief.
• Panadain Extra tablet Extra-strength analgesic tablet for pain and fever relief.
• Panadain Night tablet Night-time analgesic tablet for pain relief with sleep-aid properties.
• PREZOLDAIN Tablets Proton pump inhibitor tablets for acid-related conditions.
• KANADAIN Caplets Caplet formulation for specified therapeutic use.
• DIAZEDAIN Tablets (2 mg / 5 mg) Tablets in 2 mg and 5 mg dosage strengths for the specified therapeutic application.
• NO FLU Coated Tablets Coated tablets for cold and flu symptom relief.
• ALERDAIN Tablets Antihistamine tablets for allergy relief.
• Ciprodain Tablet 500 mg Antibiotic tablet containing ciprofloxacin for bacterial infections.
• CONGESTALAIN Caplets Decongestant caplets for nasal congestion relief.
• CYPRODAD Tablets Antibiotic tablets for bacterial infections.
• NAPROXDAIN Tablets NSAID tablets containing naproxen for pain and inflammation.
• LIBROXADAIN Sugar Coated Tablets Sugar-coated antibiotic tablets.
• DEXAMETHASONE Tablets Corticosteroid tablets for anti-inflammatory and immunosuppressive therapy.
• CALCIUM Tablets Calcium supplement tablets for bone health.
• NYSTADAD Coated Tablets Antifungal coated tablets.
• CO-TRIMOXAZOLE Tablets Antibiotic combination tablets for bacterial infections.
• VITADIN C Chewable Tablets Chewable vitamin C supplement tablets.
• PROFEDAIN Tablets (200 mg / 400 mg) Tablet dosage form available in 200 mg and 400 mg strengths.
• SPASMODAIN Sugar Coated Tablets Antispasmodic sugar-coated tablets.
• Vitadin C 500 mg Tablets Vitamin C 500 mg supplement tablets.
• PLAVEDAIN Tablets (Clopidogrel 75 mg) Antiplatelet pharmaceutical tablet product containing clopidogrel 75 mg.
• ZINCODAD Tablets Zinc supplement tablets.
• GASTEREDAIN PLUS Banana Flavor Oral Suspension Oral suspension with banana flavor formulated for pediatric use.
• GASTEREDALIN PLUS Mint Flavor Oral Suspension Oral suspension with mint flavor.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Regional players

• EIPICO (Egyptian International Pharmaceutical Industries): One of the largest generic pharmaceutical manufacturers in the Arab world, producing tablets, capsules, syrups, and ointments with active export presence in MENA including Iraq, directly comparable in product format.

Direct peers

• Al-Kindi Pharmaceutical Industries: An Iraqi private-sector manufacturer of generic human medicines across tablets, syrups, and injectables, directly comparable in geography, customer base (Iraqi pharmacies and hospitals), and product mix.
• State Company for Drug Industries (Iraq): Iraq's state-owned generic pharmaceutical manufacturer producing tablets, capsules, syrups, and injectables for the public healthcare system, serving the same end customers and competing on similar government tenders.

Broad incumbents

• Tabuk Pharmaceuticals: Saudi-headquartered generics manufacturer producing tablets, capsules, and syrups across multiple therapeutic categories; comparable dosage-form range and presence in MENA tenders, including Iraq.
• SPIMACO Addwaeih: Saudi-based pharmaceutical manufacturer producing generics across tablets, syrups, and creams with regional MENA distribution; comparable in dosage-form breadth and therapeutic categories to Wadi Al-Rafidain.
• Julphar (Gulf Pharmaceutical Industries): A large UAE-based generic and consumer health manufacturer producing tablets, syrups, and topical dosage forms, frequently exported into Iraq and other MENA markets, comparable in product format and channel.
• Hikma Pharmaceuticals: A leading MENA-headquartered generic and specialty injectable manufacturer with a deep presence in Iraq; comparable in therapeutic categories and customer base, though far larger and geographically diversified.

Emerging players

• Pharma International (Jordan): Jordan-based generic manufacturer producing tablets, syrups, and topical forms with an explicit MENA regional focus; comparable dosage formats and therapeutic categories, though larger scale and broader geography.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/@alrafidain-pharma
• Facebookfacebook.com/wadialrafidin
• Instagraminstagram.com/wadialrafidain
• LinkedInlinkedin.com/company/wadi-alrafidain

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wadi Al-Rafidain Company